New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and

Humans Antineoplastic Agents / pharmacology Benzothiazoles / pharmacology Cell Proliferation Drug Screening Assays, Antitumor MCF-7 Cells Molecular Docking Simulation Molecular Structure Protein Kinase Inhibitors / pharmacology Sorafenib / pharmacology Structure-Activity Relationship Vascular Endothelial Growth Factor Receptor-2 / metabolism
134-thiadiazoles 2-Aminobenzothiazole VEGFR-2 inhibition cyanothiouracils thiazolidine-24-diones

Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2023
Historique:
entrez: 24 1 2023
pubmed: 25 1 2023
medline: 26 1 2023
Statut: ppublish

Résumé

A new series of 2-aminobenzothiazole hybrids linked to thiazolidine-2,4-dione

Identifiants

DOI: 10.1080/14756366.2023.2166036 PMID: 36691927 PMC: PMC9879182
pubmed: 36691927
doi: 10.1080/14756366.2023.2166036
pmc: PMC9879182
doi:

Substances chimiques

Antineoplastic Agents 0
Benzothiazoles 0
Protein Kinase Inhibitors 0
Sorafenib 9ZOQ3TZI87
Vascular Endothelial Growth Factor Receptor-2 EC 2.7.10.1
KDR protein, human EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2166036

Références

Am J Gastroenterol. 2012 Jan;107(1):53-5
pubmed: 22218030
Pharmacol Res. 2016 Jan;103:26-48
pubmed: 26529477
J Med Chem. 2001 Apr 26;44(9):1446-55
pubmed: 11311068
Proteins. 1999 Nov 1;37(2):228-41
pubmed: 10584068
Molecules. 2012 Mar 30;17(4):3933-44
pubmed: 22466853
Bioorg Chem. 2020 Sep;102:104090
pubmed: 32683176
J Thorac Oncol. 2011 Aug;6(8):1418-25
pubmed: 21597387
Bioorg Chem. 2021 Feb;107:104569
pubmed: 33387732
Science. 2006 May 26;312(5777):1162-5
pubmed: 16728627
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
pubmed: 17016424
Bioorg Chem. 2021 Mar;108:104553
pubmed: 33376012
Anticancer Agents Med Chem. 2009 Nov;9(9):944-51
pubmed: 20225999
Bioorg Med Chem. 2008 Apr 1;16(7):3626-31
pubmed: 18295491
Bioorg Chem. 2022 Jul;124:105809
pubmed: 35447406
Anticancer Agents Med Chem. 2018;18(11):1606-1616
pubmed: 29745341
Arch Pharm (Weinheim). 2019 Jan;352(1):e1800170
pubmed: 30488989
J Med Chem. 1996 Aug 16;39(17):3375-84
pubmed: 8765521
Mol Cancer Ther. 2004 Dec;3(12):1565-75
pubmed: 15634650
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
S Afr J Bot. 2021 Sep;141:278-289
pubmed: 34092840
Oncotarget. 2016 Jul 12;7(28):44545-44557
pubmed: 27329593
Molecules. 2020 Nov 07;25(21):
pubmed: 33171861
ACS Med Chem Lett. 2015 Feb 12;6(4):455-60
pubmed: 25893049
Chem Biol Drug Des. 2019 May;93(5):934-948
pubmed: 30689282
Phytother Res. 2018 Jul;32(7):1273-1288
pubmed: 29468851
Eur J Med Chem. 2016 Jan 1;107:165-79
pubmed: 26590508
Respir Med. 2014 Jul;108(7):1023-30
pubmed: 24834811
J Enzyme Inhib Med Chem. 2022 Dec;37(1):39-50
pubmed: 34894962
Mini Rev Med Chem. 2020;20(1):12-23
pubmed: 31288719
Eur J Med Chem. 2019 Nov 15;182:111609
pubmed: 31445229
J Med Chem. 2013 Jul 11;56(13):5335-50
pubmed: 23750537
Nat Biotechnol. 2005 Jun;23(6):639
pubmed: 15940222
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18281-9
pubmed: 22988103
Biochem Biophys Res Commun. 2007 May 4;356(2):323-8
pubmed: 17367763
J Enzyme Inhib Med Chem. 2020 Dec;35(1):265-279
pubmed: 31790602
Bioorg Chem. 2020 Jan;95:103537
pubmed: 31884142
Arch Pharm (Weinheim). 2019 Dec;352(12):e1900178
pubmed: 31596514
Expert Rev Anticancer Ther. 2017 Jul;17(7):577-584
pubmed: 28633552
Bioorg Chem. 2020 Aug;101:103987
pubmed: 32540783
Bioorg Med Chem Lett. 2011 Feb 15;21(4):1097-101
pubmed: 21262571
Eur J Med Chem. 2010 Nov;45(11):5420-7
pubmed: 20869793
Eur J Med Chem. 2016 Jan 27;108:674-686
pubmed: 26735909
RSC Adv. 2020 Oct 6;10(60):36806-36817
pubmed: 35517953
Bioorg Med Chem Lett. 2007 Jan 1;17(1):255-9
pubmed: 17046248
Antioxidants (Basel). 2019 Sep 03;8(9):
pubmed: 31484451
Bioorg Chem. 2020 Jan;94:103422
pubmed: 31812261
Bioorg Chem. 2022 May;122:105710
pubmed: 35278776
Cancer Cell Int. 2017 Jan 3;17:4
pubmed: 28053599
Nature. 2001 May 17;411(6835):342-8
pubmed: 11357141
J Inflamm Res. 2021 Feb 03;14:253-263
pubmed: 33568930
J Immunol Methods. 1986 May 22;89(2):271-7
pubmed: 3486233
Eur J Med Chem. 2018 Aug 5;156:774-789
pubmed: 30055463
Eur J Med Chem. 2022 Dec 15;244:114827
pubmed: 36242988
J Med Chem. 2006 Jan 12;49(1):179-85
pubmed: 16392802
Eur J Med Chem. 2020 Dec 1;207:112762
pubmed: 32898763
Sci Rep. 2016 Apr 15;6:24460
pubmed: 27080011
J Comput Aided Mol Des. 1998 Jul;12(4):309-23
pubmed: 9777490
J Tradit Complement Med. 2018 Oct 05;9(4):353-363
pubmed: 31453132
Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98
pubmed: 12191602
Eur J Pharm Sci. 2020 Nov 1;154:105512
pubmed: 32801003
Int J Biol Sci. 2009;5(1):44-51
pubmed: 19159010
Bioorg Med Chem Lett. 2020 Aug 1;30(15):127281
pubmed: 32527460

Auteurs

Mohammad M Al-Sanea (MM)

Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Abdelrahman Hamdi (A)

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Ahmed A B Mohamed (AAB)

Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Hamed W El-Shafey (HW)

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Mahmoud Moustafa (M)

Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Abdullah A Elgazar (AA)

Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.

Wagdy M Eldehna (WM)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
ORCID: 0000-0001-6996-4017

Hidayat Ur Rahman (H)

Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Della G T Parambi (DGT)

Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
ORCID: 0000-0002-3954-4879

Rehab M Elbargisy (RM)

Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Samy Selim (S)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.

Syed Nasir Abbas Bukhari (SNA)

Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Omnia Magdy Hendawy (O)

Department of Pharmacology, College of Pharmacy, Jouf University, Aljouf, Saudi Arabia.

Samar S Tawfik (SS)

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzothiazoles › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de criblage d'agents antitumoraux › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Cellules MCF-7 › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Sorafénib › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › New benzothiazole hybrids as potential VEGFR-2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs aux facteurs de croissance endothéliale vasculaire › Récepteur-2 au facteur croissance endothéliale vasculaire › New benzothiazole hybrids as potential VEGFR-2...